Who we are

Leadership

Our team

Robert Geho, MBA

Co-Founder and Chief Executive Officer

Arrow

Robert Geho has more than twenty-five years of experience as an entrepreneurial business leader focused primarily on working with leading innovators in leading edge diabetes drug development. After being diagnosed with type 1 diabetes while in business school, he pivoted from undergraduate training as a classical musician to a career in the life sciences. Under his leadership, Diasome has advanced to a preeminent position in global insulin development, supported by prominent investors in type 1 and type 2 diabetes and by a who's who of internationally recognized clinical leaders in diabetes research.
 
Over the past two decades, Robert has formed and led teams that have achieved multiple firsts in diabetes research and development, including the first human trial of liver-targeted insulin, the first phase 2b oral insulin trial, and the first phase 2b liver targeted rapid acting insulin trial. These programs have made significant contributions to the field's understanding of restoring normal insulin physiology and glucose metabolism.
 
As both a patient and a life sciences professional, he combines experience in complex financing transactions, regulatory strategy, and drug development with deeply personal insights into the critical issues facing people with diabetes.
 
Robert received his undergraduate degree in a joint program from the Cleveland Institute of Music (CIM) and Case Western Reserve University (CWRU) and an MBA from CWRU. He currently serves as Vice-Chair of the Board at CIM and previously was a board member of The Diabetes Hands Foundation, one of the first global online advocacy organizations for people with diabetes.

Marc Penn, M.D., Ph.D.

Chief Medical Officer

Arrow

Dr. Penn is a cardiologist and director of research of the cardiovascular medicine fellowship at the Summa Cardiovascular Institute. He also serves as professor of medicine and integrative medical sciences at Northeast Ohio Medical University, where he leads the Skirball Laboratory for Cardiovascular Cellular Therapeutics. Previously, Dr. Penn was a cardiologist at the Cleveland Clinic, where he served as the director of the Coronary Intensive Care Unit, director of the Experimental Animal Laboratory, director of the Bakken Heart-Brain Institute and the founding director of the Center for Cardiovascular Cell Therapy.

Dr. Penn completed his undergraduate and postgraduate work at Case Western Reserve University completing a Ph.D. in biomedical engineering in 1989 and earning his M.D. in 1994. He is board certified in internal medicine and cardiovascular medicine.

W. Blair Geho, M.D., Ph.D.

Co-founder and Chief Scientific Officer

Arrow

Dr. Geho has spent his career in pharmaceutical research and development at both Fortune 100 and biotechnology companies.  As head of pharmaceutical research at the Procter & Gamble Company, he led the development of Didronel, the first approved bisphosphonate drug for treating bone disease, and Osteoscan, the first bone imaging agent.  In metabolism and endocrinology, Dr. Geho’s research has been published in leading journals over several decades, and he is recognized as a thought leader in the role of the liver in glucose metabolism and in the design of pharmaceutical systems to address dysregulation of glucose in the liver.  

He received his undergraduate degree in Chemistry from Bethany College (Bethany, West Virginia), and he was one of the United States’ first recipients of an NIH funded combined MD/PhD degree in Medicine and Pharmacology from Case Western Reserve University (Cleveland, Ohio).  During his doctoral training, his primary advisor and mentor was Nobel Laureate Earl Sutherland, MD, discoverer of the cyclic AMP second messenger system. Upon graduating from Medical School, he joined the School’s faculty in the Departments of Surgery and Pharmacology as one of the youngest instructors in the history of the University.

From 2011-2018, Dr. Geho served as co-chief translational officer of the CWRU School of Medicine and is currently an Adjunct Professor of Medicine at CWRU. Dr. Geho has over twenty-five issued US Patents in the field of diabetes and targeted drug delivery.

Douglas Muchmore, M.D.

Chief Technology Officer

Arrow

Dr. Muchmore joined Diasome in 2016 and has led the execution of multiple HDV Insulin human clinical trials, including the Company’s ISLE-1 Phase 2b study of HDV Insulin in patients with Type 1 diabetes.  He has been a clinical consultant working almost exclusively in diabetes-related endeavors for the past four years.

Previously, Dr. Muchmore worked as a consulting endocrinologist at Scripps Clinic and Research Foundation. He received his medical degree from University of California San Diego School of Medicine. He has held and continues to hold numerous consulting and medical advisory roles for large pharmaceutical companies, including Eli Lilly, Halozyme Therapeutics and Kinexum Services.

Christine Smith, Ph.D.

Chief Manufacturing Officer

Arrow

Christine has more than 20 years of experience in pharmaceutical development providing professional expertise in the chemistry, manufacturing, and controls (CMC) area from the pre-clinical stage through commercialization. Christine has had hands-on experience in the areas of active ingredient, formulation, process, manufacturing, analytical methods, regulatory strategy, quality, and technical writing. She has experience working with peptides, proteins, antibody-drug conjugates, small-molecules, parenterals, orals, non-conventional formulations, and drug-device combination products.

For the past 10 years Christine has been an owner and principal at Pharmalytical Consulting LLC providing CMC expertise to companies with a variety of clinical indications.  Prior to consulting, Christine served as Executive Director, Product Development at Amylin Pharmaceuticals where she led all aspects of CMC department.

Christine holds a Bachelor of Science in Biophysics & Chemistry from Trinity University; and a Masters of Science in Environmental Engineering Science and Ph.D. in Chemical Physics from the California Institute of Technology.

Kent Manson

Vice President, Strategy & Commercial Development

Arrow

Kent joined Diasome in 2020 as Vice President of Strategy & Commercial Development.

Prior to joining Diasome Kent led the development of the North American Health Practice at Marcus Thomas, a leading independent marketing consultancy. Prior to Marcus Thomas, Kent held numerous leadership positions focused on corporate strategy, business development, and brand strategy at WPP and flourish. Throughout his tenure Kent played key roles in commercial growth for Alkermes, BMS, Bayer and Zimmer Biomet.

Kent has completed advanced studies in Management, Strategy & Innovation at the MIT Sloan School of Management

Martin Lafontaine

Commercial Advisor

Arrow

Mr. Lafontaine has 21 years of experience within the pharmaceutical, medical device and digital health industry. He possesses strong expertise in commercial go-to-market product launch excellence, marketing, corporate development, and business development, in Canada, the US, and internationally.

Martin recently acts as an advisor to numerous development-stage pharmaceutical and medical device companies, in the field of diabetes. Prior to this, Martin held the role of Chief Commercial Officer for Locemia Solutions, a Montreal based company developing nasal glucagon for the rescue treatment of hypoglycemia, acquired by Eli Lilly in 2015.
His passion for diabetes has solid roots, beginning at age 13 when he was diagnosed with type 1 diabetes.  He authored a chapter in the book, “Successful Men With Diabetes.”

Scientific advisory board

Bruce Bode M.D., FACE

 

Arrow

Dr. Bode is an expert in diabetes at the Atlanta Diabetes Associates and is a clinical associate professor at Emory University in the Department of Medicine. He has served on the board of directors of the Atlanta chapters of the Juvenile Diabetes Research Foundation (JDRF) and the American Diabetes Association (ADA).

Bode serves on the board of directors of Glytec and is a member of the JDRF research team validating the efficacy and safety of real-time continuous glucose monitoring (CGMS).

Jeremy Pettus, M.D.

 

Arrow

Eric Edidin formed Endo Ventures in 2013, soon after his then toddler daughter was diagnosed with diabetes. Endo was founded in response to a deficit of early-stage capital focused on companies impacting diabetes and other major global health problems.

Mr. Edidin is also president of Three B Holdings, a private family investment company, and co-founded Archer Capital Management an institutional asset management firm in 2006. Previously, he was a portfolio manager and co-head of credit investments at York Capital Management, a member of Morgan Stanley Capital Partners global private equity investment team and Blackstone Group’s restructuring advisory team. Mr. Edidin is an executive board member of the JDRF of Los Angeles, and member of the investment committee of the Jewish Communal Fund of NY and the Jewish Federation of Los Angeles.

Eric holds a B.B.A. degree with highest distinction from the University of Michigan, and an M.B.A from Harvard Business School.

Our BOARD of DIRECTORS

Robert Geho, MBA

Co-Founder and Chief Executive Officer

Arrow

Robert Geho has more than twenty-five years of experience as an entrepreneurial business leader focused primarily on working with leading innovators in leading edge diabetes drug development. After being diagnosed with type 1 diabetes while in business school, he pivoted from undergraduate training as a classical musician to a career in the life sciences. Under his leadership, Diasome has advanced to a preeminent position in global insulin development, supported by prominent investors in type 1 and type 2 diabetes and by a who's who of internationally recognized clinical leaders in diabetes research.
 
Over the past two decades, Robert has formed and led teams that have achieved multiple firsts in diabetes research and development, including the first human trial of liver-targeted insulin, the first phase 2b oral insulin trial, and the first phase 2b liver targeted rapid acting insulin trial. These programs have made significant contributions to the field's understanding of restoring normal insulin physiology and glucose metabolism.
 
As both a patient and a life sciences professional, he combines experience in complex financing transactions, regulatory strategy, and drug development with deeply personal insights into the critical issues facing people with diabetes.
 
Robert received his undergraduate degree in a joint program from the Cleveland Institute of Music (CIM) and Case Western Reserve University (CWRU) and an MBA from CWRU. He currently serves as Vice-Chair of the Board at CIM and previously was a board member of The Diabetes Hands Foundation, one of the first global online advocacy organizations for people with diabetes.

W. Blair Geho, M.D., Ph.D.

Co-founder and Chief Scientific Officer

Arrow

Dr. Geho has spent his career in pharmaceutical research and development at both Fortune 100 and biotechnology companies.  As head of pharmaceutical research at the Procter & Gamble Company, he led the development of Didronel, the first approved bisphosphonate drug for treating bone disease, and Osteoscan, the first bone imaging agent.  In metabolism and endocrinology, Dr. Geho’s research has been published in leading journals over several decades, and he is recognized as a thought leader in the role of the liver in glucose metabolism and in the design of pharmaceutical systems to address dysregulation of glucose in the liver.  

He received his undergraduate degree in Chemistry from Bethany College (Bethany, West Virginia), and he was one of the United States’ first recipients of an NIH funded combined MD/PhD degree in Medicine and Pharmacology from Case Western Reserve University (Cleveland, Ohio).  During his doctoral training, his primary advisor and mentor was Nobel Laureate Earl Sutherland, MD, discoverer of the cyclic AMP second messenger system. Upon graduating from Medical School, he joined the School’s faculty in the Departments of Surgery and Pharmacology as one of the youngest instructors in the history of the University.

From 2011-2018, Dr. Geho served as co-chief translational officer of the CWRU School of Medicine and is currently an Adjunct Professor of Medicine at CWRU. Dr. Geho has over twenty-five issued US Patents in the field of diabetes and targeted drug delivery.

Frank McCaney

Chairman of the Board of Directors, NMS Labs

Arrow

Frank McCaney is the Chairman of the Board of Directors at NMS Labs.  He is an accomplished executive with more than 25 years of demonstrated growth and success in medical devices and drug development.  Experienced in Business Management at the CEO level, drug development, raising capital, M&A, Sales and Marketing, and turnarounds.

Mr. McCaney previously served as CEO of Strata Skin Sciences (SSKN: NASDAQ) and before that he was CEO of Corpak MedSystems, a private equity-backed medical device company in the field of enteral feeding. Corpak was sold to Halyard Health (HYH: NYSE) for $174 million in May 2016. Prior to Corpak, he was the founder and CEO of Nitric BioTherapeutics, a venture backed-medical technology company from 2006 until 2012. Prior to Nitric Bio, he was a senior executive at Viasys Healthcare, Inc. (VAS: NYSE), a medical technology company focusing on respiratory, neurology, medical disposable and orthopedic products and had a lead role in spinning Viasys out of Thermo Electron Corporation (TMO: NYSE). While at Viasys, Mr. McCaney had several responsibilities including strategy, business development and investor relations. Frank is also the Chairman of the Board of Allevi Inc, a Tissue Bioprinting company located in Philadelphia.

Thomas McDonald

Founder and CEO, McDonald Partners

Arrow

Thomas McDonald is the founder of McDonald Partners in Cleveland, Ohio.
He served as President and CEO of Wayne Hummer Investments in Chicago from 2003-2005.  Here, Tom had total responsibility for the financial success of the company and was charged with growing the organization through the addition of high-quality financial advisors to service high net-worth clients of the parent company’s banks. 

Prior to joining Wayne Hummer, Tom spent 12 years with McDonald Investments in Cleveland.  He began as Director of Sales Development and progressed in responsibility to ultimately become Director of the Private Client Group.  In that capacity, Tom established the Investor Services Group and developed products and services dedicated to the affluent investor. 

In 1998, KeyBank bought McDonald Investments and Tom was responsible for integrating the Private Bank and Private Client Group.  He successfully integrated the organizations and was appointed to manage the Private Bank as well as the Private Client Group of McDonald Investments.  The combination allowed the firm to fully deliver all aspects the combined wealth management Key had to offer.  At the same time, Tom was responsible for growing the firm and increased revenues from just over $100 million to over $600 million – including Private Banking revenues.  Along with the revenue growth, Tom grew the number of financial advisors from 120 to over 600.  During his tenure at McDonald Investments, Tom served on various committees including McDonald Investments’ Board of Directors, the firm’s Capital Commitment Committee and the Compliance Committee.

Tom is actively involved in the industry through his participation in the Securities Industry Financial Markets Association, currently serving on the Board of Directors of SIFMA and serving as Chair of the Board’s Small Firms Committee.

In addition to industry involvement, he has been active in civic organizations during his career.  Currently he serves on the Board of Trustees of the MetroHealth System, the third largest health system in Northeast Ohio.  He has served on that Board since 2008 and served as its Chair from March of 2013 until March of 2019 and serves on a number of Metro’s Board committees.

Marc Penn, M.D., Ph.D.

Chief Medical Officer

Arrow

Dr. Penn is a cardiologist and director of research of the cardiovascular medicine fellowship at the Summa Cardiovascular Institute. He also serves as professor of medicine and integrative medical sciences at Northeast Ohio Medical University, where he leads the Skirball Laboratory for Cardiovascular Cellular Therapeutics. Previously, Dr. Penn was a cardiologist at the Cleveland Clinic, where he served as the director of the Coronary Intensive Care Unit, director of the Experimental Animal Laboratory, director of the Bakken Heart-Brain Institute and the founding director of the Center for Cardiovascular Cell Therapy.

Dr. Penn completed his undergraduate and postgraduate work at Case Western Reserve University completing a Ph.D. in biomedical engineering in 1989 and earning his M.D. in 1994. He is board certified in internal medicine and cardiovascular medicine.

Peter A. Tollman, Ph.D.

Senior Partner Emeritus, Boston Consulting Group

Arrow

Peter Tollman is a Boston-based senior partner and managing director at The Boston Consulting Group which he joined in 1989. He leads BCG's People and Organization Practice in North America. Prior leadership roles have included global leadership of BCG's Biopharmaceutical's Sector and its R&D Topic. He holds a PhD in Engineering from the University of Cape Town South Africa and an MBA with distinction from Columbia Business School.

As one of BCG's most experienced client-service partners Peter has helped many of the world's leading corporations improve the competitiveness and performance of their organizations. His work has spanned the globe and involved a wide range of engagements including organization restructurings, governance redesigns, culture change, shareholder value and growth-enhancement initiatives, enterprise-wide transformations and coaching CEOs and other senior leaders through leadership transitions.

Eric Edidin

Board Observer, Founding and Managing Partner, Endo Investors

Arrow

Eric Edidin formed Endo Ventures in 2013, soon after his then toddler daughter was diagnosed with diabetes. Endo was founded in response to a deficit of early-stage capital focused on companies impacting diabetes and other major global health problems.

Mr. Edidin is also president of Three B Holdings, a private family investment company, and co-founded Archer Capital Management an institutional asset management firm in 2006. Previously, he was a portfolio manager and co-head of credit investments at York Capital Management, a member of Morgan Stanley Capital Partners global private equity investment team and Blackstone Group’s restructuring advisory team. Mr. Edidin is an executive board member of the JDRF of Los Angeles, and member of the investment committee of the Jewish Communal Fund of NY and the Jewish Federation of Los Angeles.

Eric holds a B.B.A. degree with highest distinction from the University of Michigan, and an M.B.A from Harvard Business School.

Diasome logo

Contact

10000 Cedar Avenue
Suite 6
Cleveland, OH 44106
+1.216.444.7110

Media Contact

Kent Manson
+1.720.891.7644